| Primary |
| Atrial Fibrillation |
22.4% |
| Product Used For Unknown Indication |
22.4% |
| Hypertension |
15.3% |
| Drug Use For Unknown Indication |
9.2% |
| Arrhythmia |
6.1% |
| Prophylaxis |
4.1% |
| Pain |
3.1% |
| Asthma |
2.0% |
| Atrial Flutter |
2.0% |
| Cardiac Failure |
2.0% |
| Tachycardia |
2.0% |
| Abdominal Pain Upper |
1.0% |
| Amyotrophic Lateral Sclerosis |
1.0% |
| Arrhythmia Prophylaxis |
1.0% |
| Autophony |
1.0% |
| Blood Cholesterol |
1.0% |
| Blood Cholesterol Abnormal |
1.0% |
| Blood Pressure |
1.0% |
| Chronic Obstructive Pulmonary Disease |
1.0% |
| Coagulopathy |
1.0% |
|
| Trifascicular Block |
14.3% |
| Hypotension |
11.9% |
| Syncope |
7.1% |
| Drug Interaction |
4.8% |
| Intentional Self-injury |
4.8% |
| Malaise |
4.8% |
| Presyncope |
4.8% |
| Renal Failure Acute |
4.8% |
| Sinobronchitis |
4.8% |
| Sinus Bradycardia |
4.8% |
| Tremor |
4.8% |
| Urticaria |
4.8% |
| Visual Impairment |
4.8% |
| Vomiting |
4.8% |
| Electrocardiogram Qrs Complex Prolonged |
2.4% |
| Eyelid Oedema |
2.4% |
| Jaundice Cholestatic |
2.4% |
| Muscular Weakness |
2.4% |
| Paraesthesia |
2.4% |
| Scrotal Pain |
2.4% |
|
| Secondary |
| Atrial Fibrillation |
21.0% |
| Hypertension |
21.0% |
| Product Used For Unknown Indication |
21.0% |
| Drug Use For Unknown Indication |
16.1% |
| Cardiac Failure |
6.5% |
| Amyotrophic Lateral Sclerosis |
4.8% |
| Atrial Flutter |
3.2% |
| Cardiac Disorder |
3.2% |
| Arrhythmia |
1.6% |
| Peptic Ulcer |
1.6% |
|
| Death |
18.8% |
| Oxygen Saturation Decreased |
18.8% |
| Pulmonary Oedema |
12.5% |
| Electrocardiogram Qrs Complex Prolonged |
6.3% |
| Febrile Neutropenia |
6.3% |
| Malaise |
6.3% |
| Palpitations |
6.3% |
| Presyncope |
6.3% |
| Sinus Bradycardia |
6.3% |
| Sleep Apnoea Syndrome |
6.3% |
| Supraventricular Tachycardia |
6.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
18.1% |
| Hypertension |
16.3% |
| Drug Use For Unknown Indication |
14.5% |
| Atrial Fibrillation |
8.8% |
| Arrhythmia |
7.9% |
| Glaucoma |
4.8% |
| Non-small Cell Lung Cancer |
3.5% |
| Osteoporosis |
3.1% |
| Thrombosis Prophylaxis |
3.1% |
| Cardiac Insufficiency |
2.2% |
| Rheumatoid Arthritis |
2.2% |
| Type 2 Diabetes Mellitus |
2.2% |
| Chemotherapy |
1.8% |
| Depression |
1.8% |
| Migraine |
1.8% |
| Neoplasm Malignant |
1.8% |
| Open Angle Glaucoma |
1.8% |
| Prophylaxis |
1.8% |
| Back Pain |
1.3% |
| Hypercholesterolaemia |
1.3% |
|
| Syncope |
11.8% |
| Metabolic Acidosis |
9.8% |
| Renal Failure Acute |
7.8% |
| Presyncope |
5.9% |
| Thrombocythaemia |
5.9% |
| Burnout Syndrome |
3.9% |
| Cerebrovascular Accident |
3.9% |
| Death |
3.9% |
| International Normalised Ratio Decreased |
3.9% |
| Mucosal Inflammation |
3.9% |
| Myopathy |
3.9% |
| Off Label Use |
3.9% |
| Restlessness |
3.9% |
| Somnolence |
3.9% |
| Subdural Haematoma |
3.9% |
| Sudden Death |
3.9% |
| Tachycardia |
3.9% |
| Transient Ischaemic Attack |
3.9% |
| Vision Blurred |
3.9% |
| Wolff-parkinson-white Syndrome |
3.9% |
|
| Interacting |
| Product Used For Unknown Indication |
22.7% |
| Atrial Fibrillation |
13.6% |
| Hypertension |
13.6% |
| Coronary Artery Disease |
9.1% |
| Dyslipidaemia |
9.1% |
| Extrasystoles |
9.1% |
| Fibrillation |
9.1% |
| Osteoporosis |
9.1% |
| Hyperlipidaemia |
4.5% |
|
| Palpitations |
50.0% |
| Drug Interaction |
37.5% |
| Vomiting |
12.5% |
|
